Somewhat Positive Press Coverage Likely to Affect Albany Molecular Research (AMRI) Share Price

News coverage about Albany Molecular Research (NASDAQ:AMRI) has trended somewhat positive this week, AlphaOne Sentiment Analysis reports. AlphaOne, a subsidiary of Accern, ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Albany Molecular Research earned a news sentiment score of 0.07 on AlphaOne’s scale. AlphaOne also assigned news stories about the biotechnology company an impact score of 70 out of 100, meaning that recent press coverage is likely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted AlphaOne Sentiment Analysis’s rankings:

Insider Buying and Selling by Quarter for Albany Molecular Research (NASDAQ:AMRI)

A number of research firms recently issued reports on AMRI. First Analysis downgraded Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a report on Monday. J P Morgan Chase & Co downgraded Albany Molecular Research from an “overweight” rating to a “neutral” rating in a report on Thursday, June 8th. William Blair downgraded Albany Molecular Research from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 6th. Finally, Morgan Stanley downgraded Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price objective for the company. in a report on Thursday, May 11th. They noted that the move was a valuation call.

Albany Molecular Research (NASDAQ AMRI) traded up 0.32% on Friday, hitting $21.64. The company had a trading volume of 1,181,602 shares. Albany Molecular Research has a one year low of $12.51 and a one year high of $22.17. The company’s market capitalization is $900.31 million. The stock’s 50-day moving average price is $18.69 and its 200 day moving average price is $17.04.

Albany Molecular Research (NASDAQ:AMRI) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Albany Molecular Research had a positive return on equity of 11.97% and a negative net margin of 11.26%. The business had revenue of $163.80 million during the quarter, compared to analyst estimates of $161.43 million. During the same period in the previous year, the company posted $0.07 EPS. The firm’s revenue was up 55.1% compared to the same quarter last year. On average, analysts expect that Albany Molecular Research will post $1.13 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by sleekmoney and is owned by of sleekmoney. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *